Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30‐year nationwide cohort of 1478 patients under 18 years of ageCohort Study · 2016 · 126 citations
2Response to initial treatment of multisystem langerhans cell histiocytosis: An important prognostic indicatorPrognostic Study · 2002 · 146 citations
3Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 studyEarly-Phase Clinical Trial · 2015 · 164 citations
4Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioningRetrospective Study · 2015 · 77 citations
5<i>BRAF</i> Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line TherapyRegistry Study · 2016 · 343 citations
6Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other TherapiesHuman Clinical Trial · 2013 · 93 citations
7Vemurafenib Use in an Infant for High-Risk Langerhans Cell HistiocytosisCase Report · 2015 · 112 citations
8Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCHOriginal Research · 2017 · 42 citations
9Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and DexamethasoneJournal of Clinical Oncology · 2026
10Image-Based Consensus Molecular Subtyping Refines Prognostication in Stage II/III Colorectal Cancer: A Retrospective Analysis of the SCOT TrialJournal of Clinical Oncology · 2026

More from Journal of Clinical Oncology

More from University College London